After EMPA-REG OUTCOME and LEADER: Already a 'New Era' in Therapy of Type 2 Diabetes?

Schatz H.

首页> 外文期刊>Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association >After EMPA-REG OUTCOME and LEADER: Already a 'New Era' in Therapy of Type 2 Diabetes?

【24h】

After EMPA-REG OUTCOME and LEADER: Already a 'New Era' in Therapy of Type 2 Diabetes?

机译：在EMPA-REG结局和领导者之后：2型糖尿病的治疗已经进入“新时代”了吗？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Critical discussion of the cardiovascular findings with empagliflozin (EMPA-REG OUTCOME Study) and liraglutide (LEADER Study) and the consequences.

机译：依帕列净（EMPA-REG OUTCOME研究）和利拉鲁肽（LEADER研究）对心血管发现的严格讨论及其后果。

著录项

来源
《Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association 》 |2016年第8期| 共2页
作者
Schatz H.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病 ;
关键词
empagliflozin; liraglutid; cardiovascular effects; new era of treatment; add-on to metformin;

机译：恩帕格列嗪;拉拉肽;心血管效应;新的治疗时代;二甲双胍的附加药物;

相似文献

外文文献
中文文献
专利

1. After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes? [J] . Schatz H. Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association . 2016 ,第8期

机译：在EMPA-REG结局和领导者之后：2型糖尿病的治疗已经进入“新时代”了吗？
2. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials Diabetes Care 2017; 40:821-831 [J] . Feldman-Billard Sylvie Diabetes care . 2017 ,第12期

机译：减轻2型糖尿病患者的心血管风险抗体药物：综述Empa-Reg结果，领导者和维持-6试验糖尿病护理的主要心血管结果结果2017; 40：821-831.
3. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials (vol 40, pg 821, 2017) [J] . Kaul Sanjay Diabetes care . 2018 ,第3期

机译：减轻2型糖尿病患者的心血管风险：empa-reg结果，领导者和维持6次试验的主要心血管成果结果（Vol 40，PG 821,2017）审查
4. Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator^* [C] . Roberto Visentin, Michele Schiavon, Clemens Giegerich, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2018

机译：长效胰岛素在糖尿病治疗中的作用：采用UVA / Padova 1型糖尿病模拟器的Silico临床试验^*
5. Comparison of monotherapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in improving health outcomes among veteran patients with type 2 diabetes. [D] . Campbell, Heather M. 2011

机译：与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂单一疗法改善2型糖尿病退伍军人患者健康结局的比较。
6. Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME LEADER and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 [O] . Sanjay Kaul 2018

机译：勘误表。使用抗糖尿病药物减轻2型糖尿病的心血管风险：EMPA-REG成果领导者和SUSTAIN-6试验的主要心血管结果的回顾。 2017年糖尿病护理； 40：821–831
7. Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 [O] . Sylvie Feldman-Billard 2017

机译：评论Kaul。减轻2型糖尿病患者的心血管风险：empa-reg结果，领导者和维持6次试验的主要心血管成果综述。糖尿病护理2017; 40：821-831

After EMPA-REG OUTCOME and LEADER: Already a 'New Era' in Therapy of Type 2 Diabetes?

摘要

著录项

相似文献

相关主题

期刊订阅